Indo US Bio-Tech Limited reported a standalone net profit of ₹3.04 crore for the quarter ended June 30, 2026, marking a 35% decline from ₹4.70 crore in Q1FY25. While revenue from operations grew by 7% to ₹32.99 crore from ₹30.77 crore year-on-year, the profit contraction highlights margin pressure from rising production expenses and finance costs. The Board of Directors approved the unaudited financial results on August 12, 2026, following review by the Audit Committee.

The company’s total income for the quarter stood at ₹33.11 crore, up from ₹30.77 crore in Q1FY25. Other income contributed ₹12.38 lakh, a significant increase from ₹1.5 lakh in the corresponding period last year. However, total expenses rose to ₹30.03 crore from ₹25.95 crore, primarily due to higher production expenses and changes in inventory valuation.

Financial Performance Overview

Production expenses surged to ₹86.26 lakh in Q1FY26 compared to ₹88.40 lakh in Q1FY25, but this was offset by favorable changes in inventories of finished goods and work-in-progress, which reduced cost of sales by ₹12.16 lakh versus an addition of ₹6.13 lakh in the prior year. Purchase of stock-in-trade decreased significantly to ₹52.42 lakh from ₹71.51 lakh, indicating efficient inventory management or lower procurement needs.

Finance costs increased to ₹7.39 lakh from ₹4.51 lakh, reflecting higher interest outlays. Employee benefits expense remained stable at ₹3.29 lakh. Depreciation and amortization charges rose slightly to ₹2.69 lakh from ₹2.00 lakh. Other expenses declined to ₹26.69 lakh from ₹28.56 lakh, showing some control over discretionary spending.

What the Numbers Show

The divergence between revenue growth (7%) and expense growth (15.7%) reveals underlying operational inefficiencies. Although production volumes may have increased, leading to higher revenue, the associated costs did not scale proportionally. The sharp rise in finance costs suggests increased leverage or higher interest rates impacting profitability. Despite these headwinds, the company maintained positive net income, demonstrating resilience in its seed cultivation, processing, and trading business segment.

Tax expense for the quarter was ₹3.96 lakh, lower than ₹11.75 lakh in Q1FY25, partly due to deferred tax adjustments. Basic earnings per share stood at ₹1.51, down from ₹2.35 in the previous year. The statutory auditors, Bhagat & Associates, issued a limited review report with an unmodified opinion, confirming compliance with Ind-AS 34 and SEBI Listing Regulations.

Indo Us Bio-Tech Limited shareholders have approved the regularization of Hemanshi Darsh Soni as a non-executive independent director and the appointment of M/s. Bhagat & Associates as statutory auditor, following a remote e-voting postal ballot process. The voting period ran from July 5, 2026, to August 3, 2026, with results declared on August 5, 2026. Both resolutions secured overwhelming support, with 100% of polled votes cast in favor, signaling clear shareholder endorsement of the company’s governance appointments.

The postal ballot was conducted in compliance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Sections 108 and 110 of the Companies Act, 2013. Amrish Gandhi & Associates served as the scrutinizer for the process, overseeing the remote e-voting facility provided by National Securities Depository Limited (NSDL). The cut-off date for determining voting eligibility was June 26, 2026, with 4,774 shareholders eligible to vote on a total equity shareholding of 2,00,52,000 shares.

Voting Results Breakdown

The promoter group held 1,36,93,643 shares (68.29% of total equity) and voted entirely in favor of both resolutions. Public non-institutional shareholders, holding 63,58,357 shares, participated actively, polling 2,94,924 votes (4.64% participation rate). Of these, 2,94,919 votes were cast in favor, while only five votes were recorded against each resolution. No public institutional shareholders held stakes or participated in the vote.

Governance Implications

The regularization of Hemanshi Darsh Soni (DIN: 11659183) addresses prior procedural gaps in her initial appointment as an additional director. Her confirmation strengthens the board’s independent oversight capacity, a key metric for regulatory compliance and investor confidence. Meanwhile, the appointment of Bhagat & Associates (FRN: 101100W) as statutory auditor ensures continuity in financial reporting integrity, particularly relevant given the company’s ISO-certified operations and DSIR-recognized R&D unit.

Pursuant to Regulations 59 and Schedule XX of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, three shareholders voted against both resolutions. However, their dissenting votes represented just five shares out of 1,39,88,567 polled, indicating minimal opposition to the proposed changes. The scrutinizer’s report confirmed that all conditions under the Companies Act, 2013, and SEBI LODR regulations were fulfilled, validating the outcome.

What the Numbers Show

The near-total support from both promoter and public non-institutional shareholders underscores stable governance alignment at Indo Us Bio-Tech Limited. With promoters casting all their votes in favor and public retail investors showing a 99.9983% approval rate, the company demonstrates strong internal cohesion on critical board-level decisions. This level of consensus reduces future governance friction risks and supports smoother execution of strategic initiatives, including potential expansions in its agri-tech R&D capabilities.